The biotech sector as a whole narrowed its loss by 64% to $2.7 billion, according to consultants Ernst & Young. This is the closest the industry has come to breaking even (a trend that agrees with Nature Biotechnology's independent public biotech analysis, p. 753). The number of public biotechs jumped by double digits in every region except for Canada. Cash reserves dwindled, however, perhaps foreshadowing a continued financing slowdown this year. Still, mergers and acquisitions and partnership valuations were at record highs in 2007.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. State of the biotech sector—2007. Nat Biotechnol 26, 728 (2008). https://doi.org/10.1038/nbt0708-728
Issue Date:
DOI: https://doi.org/10.1038/nbt0708-728
